Page 18 - Labatt BTRC Annual Report 2020-2021
P. 18

Year in Review – Currently Held Grants
Dr. Uri Tabori
Clinical translation of novel immune-based combination therapies for paediatric hypermutant cancers. Stand Up To Cancer
Biological and pre-clinical studies to enable TIL therapy clinical trial in pediatric hypermutant cancers. V-foundation for Cancer Research
NanoString Counter Vantage 3D platform-based complementary diagnostic tests for precision medicine in pediatric cancers. Genome Canada
Catalyzing the University of Toronto as a global epicenter for translational research and training. Connaught Global Translational Award
A comprehensive clinical and molecular characterization of low-grade gliomas in adolescents and young adults. b.r.a.i.n.child
A Phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway. Canadian Institutes of Health Research
Biological and translational implications of replication repair deficiency and hyper mutation in human cancer. Canadian Institutes of Health Research
Molecular based approach to improve outcome for children and young adults with low-grade glioma. Canadian Institutes of Health Research
Dr. Michael Taylor
Targeting brain tumour stem cell epigenetic and molecular networks. Stand Up To Cancer Canada
Canada’s Genomics Enterprise. Canada Foundation for Innovation
Cellular and genetic heterogeneity as a therapeutic hurdle an opportunity for Ontarians with brain cancer. Ontario Institute for Cancer Research
Heterogeneity through space and time drive the clinical behaviour of childhood medulloblastoma. Canadian Institutes of Health Research
Targeting circulating metastatic cells as a novel approach for cancer therapy. V-Foundation Pediatric Cancer – Translational Award
Immunogenomics to create new therapies for high-risk childhood cancers. Stand Up To Cancer Pediatric Dream Team Translational Cancer Research Grant
Precision oncology for young people. Terry Fox Research Institute
Tackling childhood brain cancer at the root to improve survival and quality of life. Genome Canada/Canadian Institutes of Health Research
Oxygen is poison – how incorrect modelling of the human microenvironment has impeded paediatric research. Canada Foundation for Innovation
Prevention and treatment of lethal metastases in group 3 medulloblastoma. National Institutes of Health
Post-therapy metastasis: Facing the real challenge of medulloblastoma treatment. The SWIFTY Foundation
The New Roads Team – Innovative approaches to curing brain tumours. Cancer Research UK
Improving therapy by targeting the biological differences between micro and macro metastases in central nervous system tumours. Matthew Larson Foundation
Combined approaches by immune checkpoint inhibition for hypermutant cancers. American Association for Cancer Research
Developmental and predictive companion biomarkers and therapeutic monitoring for hypermutant cancers to immune checkpoint inhibition. BioCanRx
Targeting the telomere maintenance pathway for cancer diagnostics and therapeutics. Canadian Cancer Research Society
18 IMAGINE 2020-21

   16   17   18   19   20